Our People
InVivium Capital Team
Michael Liang, Ph.D.
Managing General Partner
Email
Michael Liang, Ph.D.
Managing General Partner
Michael Liang, Ph.D. is a Managing General Partner with InVivium Capital. Previously, Mike spent 16 years as a Partner with Baird Capital, overseeing healthcare investments. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, U.K.) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike serves on the Board of Directors of Onchilles Pharma and was also previously a Board Member of Alto Neuroscience (NYSE: ANRO), GreenLight Biosciences (NASDAQ: GRNA), Interlace Medical (sold to Hologic), OncoHealth (sold to Arsenal Capital Partners), Veniti (sold to Boston Scientific), and a board observer of TomoTherapy (NASDAQ: TOMO, sold to Accuray). Mike also recently served on the Board of Directors of AiCure, Jumpcode Genomics, NeoChord and Zurex Pharma, and was a Board Observer for Saranas and Virtual Incision. Mike received a B.S. in bioorganic chemistry from the University of California, Berkeley, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.
Amy Len Kobe
General Partner
Email
Amy Len Kobe
General Partner
Amy Len Kobe is a General Partner with InVivium Capital. Amy was previously a Principal with Baird Capital where she led investments on the Healthcare team. Amy is currently a Board Observer for Virtual Incision and Onchilles Pharma. She previously served on the board of directors of Cala Health, Saranas and Virtual Incision and was an observer for Jumpcode, Upfront Healthcare, OncoHealth and AiCure. Prior to Baird Capital, Amy was a venture investor with Baxter Healthcare, focused on medical devices, monitoring, and data analytics opportunities. She was also previously with Healthbox, focused on tech-enabled products and services. Amy began her career with roles at McKinsey & Company and Genentech. Amy received a B.S. and M.S. in chemical engineering from Stanford University and an MBA from Kellogg School of Management. She is also a member of the Economic Club of Chicago, where she serves on the Young Leaders Committee.
Alyse Passaglia
HR/Office Manager
Email
Alyse Passaglia
HR/Office Manager
Alyse Passaglia is an HR/Office Manager with InVivium Capital. Previously, Alyse spent 11 years at GCM Grosvenor, in both the Fund Accounting department and as a member of the Human Resources team. Alyse received a B.S. in Education from Illinois State University.
Christine Neipert, J.D., Ph.D.
IP Advisor
Christine Neipert
J.D., Ph.D., IP Advisor
Christine Neipert has over 15 years of experience in intellectual property, healthcare reimbursement, and technology commercialization. She has worked on both the entrepreneurial side, helping lead multiple funding rounds for companies such as Walden Biosciences and STAT3 Therapeutics, and on the venture capital side, assisting with target investment diligence. Christine’s expertise encompasses IP strategy and due diligence, as well as the development of commercialization pathways for innovative healthcare technologies, ensuring successful market entry and sustainability for emerging companies. She earned her PhD in Chemistry from the University of South Florida and her JD from Franklin Pierce Law Center.
Fred Robertson, M.D.
Venture Partner
Frederick Robertson
M.D., Venture Partner
Dr. Frederick Robertson, M.D. is Venture Partner with InVivium Capital. He is also a Venture Partner at Baird Capital where he has spent 10 years supporting the healthcare investment team. Prior to Baird Capital, Fred was CEO and Director of TomoTherapy Inc., where he led the company’s IPO acquisition in 2011. Prior to TomoTherapy, Fred served in a variety of senior executive roles in the medical device industry, including President and CEO of GE Marquette Medical Systems and later as Chief Clinical Officer of GE Medical Systems. Fred currently serves on the board of directors for the University of Wisconsin Foundation, the Morgridge Institute for Research, Alpha Source, Elucent Medical, Ensodata, Saranas, Virtual Incision and Zurex Pharma and has earned the National Association of Corporate Directors Directorship Certification. Fred received an MBA from San Diego State University and M.D. from University of Wisconsin Medical School, where he was also previously on faculty for the Dept of Anesthesiology at the University of Wisconsin School of Medicine and Public Health.
Dan Wolterman
Venture Partner
Dan Wolterman
Venture Partner
Dan Wolterman is a Venture Partner with InVivium Capital. Dan has over 40 years of health care executive leadership, including not-for-profit hospital systems in Florida, Indiana, Utah and Texas. Previously, he was President and CEO of Memorial Hermann Health System, where under his leadership, Memorial Hermann saw year-over-year double-digit growth, becoming the largest not-for-profit health system in Southeast Texas. Dan currently serves on the boards of BactoByte, Legacy ER/Urgent Care, NuVasive, Vizient, Saranas and Zibrio. Previously, Dan served as chair of the Greater Houston Partnership, Texas Hospital Association and American Heart Association Houston chapter. Dan has received numerous recognitions including induction into the Texas Business Hall of Fame and was named one of the “100 Most Influential People in Healthcare” by Modern Healthcare magazine from 2008-2015. Dan received a BS in business administration and MBA from the University of Cincinnati and MS in health care administration from Xavier University.
